Evidence map›Paper›PMID 37855052›Full record

ArticleHaematologica2024

Subcutaneous injection of IHP-102 prevents lung vaso-occlusion in sickle cell disease mice.

Rikesh K Dubey, Ravi Vats, Tomasz Brzoska, Tomasz W Kaminski, Omika Katoch, Jesus Tejero, Gabriel Njikang, John Paderi, Prithu Sundd

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rikesh K DubeyThrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Ravi VatsVascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA.
Tomasz BrzoskaVascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA.
Tomasz W KaminskiThrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Omika KatochThrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Jesus TejeroVascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA.
Gabriel NjikangIHP Therapeutics, San Carlos, CA.
John PaderiIHP Therapeutics, San Carlos, CA.
Prithu SunddThrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Sickle Cell Center of Excellence, University of Pittsburgh, Pittsburgh, PA. psundd@versiti.org.

Funding

Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest SyndromeR01HL128297 · NHLBI · VERSITI WISCONSIN, INC. · PI SUNDD, PRITHU · 2015 to 2025
$5.4M
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1M
CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell DiseaseR01HL166345 · NHLBI · VERSITI WISCONSIN, INC. · PI Prithu Sundd · 2023 to 2026
$3.1M
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell diseaseR44HL167473 · NHLBI · IHP THERAPEUTICS, INC. · PI JOHN PADERI, JOHN PADERI JOHN PADERI · 2023 to 2024
$2.6M
Request for Zeiss 710 multiphoton 5Live Duoscan MicroscopeS10RR028478 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WATKINS, SIMON C · 2011 to 2011
$1.1M
Request for a Nikon A1R Multiphoton MicroscopeS10OD025041 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WATKINS, SIMON C · 2018 to 2018
$870k
American Heart Association-American Stroke Association 18TPA34170588American Heart Association-American Stroke Association 19PRE34430188American Heart Association-American Stroke Association AHA828786NCRR NIH HHS S10 RR028478NHLBI NIH HHS R01 HL128297NHLBI NIH HHS R01 HL141080NHLBI NIH HHS R01 HL166345NHLBI NIH HHS R44 HL167473NIH HHS S10 OD025041
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, Sickle CellVascular DiseasesAnimalsInjections, SubcutaneousLungMice

Identifiers

PMID37855052
PMCPMC10985437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.